Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Gross Profit (2021 - 2023)

Historic Gross Profit for ADC Therapeutics (ADCT) over the last 3 years, with Q3 2023 value amounting to $763000.0.

  • ADC Therapeutics' Gross Profit fell 9898.3% to $763000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $69.3 billion, marking a year-over-year increase of 30436.79%. This contributed to the annual value of -$4.6 billion for FY2022, which is 1580731.57% down from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Gross Profit is $763000.0, which was down 9898.3% from $4.8 million recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Gross Profit registered a high of $69.3 billion during Q4 2022, and its lowest value of -$13.9 million during Q1 2021.
  • Its 3-year average for Gross Profit is $7.9 billion, with a median of $15.0 million in 2022.
  • As far as peak fluctuations go, ADC Therapeutics' Gross Profit skyrocketed by 1504580.97% in 2022, and later tumbled by 9898.3% in 2023.
  • ADC Therapeutics' Gross Profit (Quarter) stood at $17.0 billion in 2021, then soared by 307.46% to $69.3 billion in 2022, then plummeted by 100.0% to $763000.0 in 2023.
  • Its Gross Profit stands at $763000.0 for Q3 2023, versus $4.8 million for Q2 2023 and $18.4 million for Q1 2023.